<DOC>
	<DOCNO>NCT00169923</DOCNO>
	<brief_summary>The purpose study patient stage 4 5 chronic kidney disease determine whether rosiglitazone reduce inflammatory marker investigate effect intima medium thickness , calcification pulse wave velocity .</brief_summary>
	<brief_title>Anti-Inflammatory Effects Rosiglitazone Patients With Stage 4 5 Chronic Kidney Disease</brief_title>
	<detailed_description>This double-blind randomise placebo-controlled clinical multicenter trial patient stage 4 5 chronic kidney disease . Eligible patient outpatient kidney clinic patient dialysis department inform treat physician study ask join study . Following informed consent eligible patient undergo baseline evaluation follow period 48 week . Patients randomly divide two group : one group take rosiglitazone ( 4 mg first 8 week daily 8 mg next 40 week daily ) group get placebo . The original medication continue . The total follow-up 48 week . At start study 4 , 8 , 12 , 18 , 24 48 week follow-up inflammatory parameter ( CRP , h CRP , fetuin , fibrinogen ) , lipid profile , iron status , glucose insulin measure . Intima medium thickness , pulse wave velocity , bone densitometry , subjective global assessment perform 0 , 24 48 week .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Written consent Over 18 year age Stage 4 5 chronic kidney disease accord K/DOQI guideline Life span less one year Alcohol abuse Transaminases &gt; 2.5 time upper limit Diabetes mellitus Pregnancy Cardiac disease mark limitation functional capacity ( NYHA III IV ) Use immunosuppressant agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>